New immunosuppressants with potential implication in multiple sclerosis

@article{Gonsette2004NewIW,
  title={New immunosuppressants with potential implication in multiple sclerosis},
  author={Richard E Gonsette},
  journal={Journal of the Neurological Sciences},
  year={2004},
  volume={223},
  pages={87-93}
}
  • R. Gonsette
  • Published 15 August 2004
  • Medicine
  • Journal of the Neurological Sciences
New immunosuppressants are consistently developed to treat autoimmune diseases and some of them might have implications in multiple sclerosis (MS). A new antiproliferative agent, pixantrone, an analogue of mitoxantrone (MX), has a much lower cardiotoxicity and exerts the same potent immunosuppressive effects in experimental allergic encephalomyelitis (EAE). A phase I trial in MS patients is planned in the next future. New monoclonal antibodies (mAb) and other biological constructs containing… 
Mechanisms of Action for Treatments in Multiple Sclerosis
TLDR
The potential mechanisms of action of several effective therapies for MS that are currently available or in development are reviewed and the effects of each treatment are described in terms of their actions on key processes in a five-step model of MS pathogenesis.
The value of animal models for drug development in multiple sclerosis.
TLDR
It is proposed that pre-clinical trials should be started in humanized mouse models to try to circumvent rodent-human dissimilarities more systematically and limit extrapolation from EAE to multiple sclerosis.
Opportunistic infections and other risks with newer multiple sclerosis therapies
TLDR
The identification of progressive multifocal leukoencephalopathy as a risk of therapy is relatively straightforward in light of its rarity and high morbidity and mortality, but a relatively slight increased risk for more common and less disabling disorders may be overlooked.
Isogarcinol Is a New Immunosuppressant
TLDR
Oral administration of isogarcinol in mice resulted in a dose-dependent decrease in delayed type hypersensitivity (DTH) and prolonged graft survival in allogeneic skin transplantation and could serve as a new oral immunomodulatory drug for preventing transplant rejection, and for long-term medication in autoimmune diseases.
Lessons from the Past and Future Approaches for Immunologic Therapies in Multiple Sclerosis
TLDR
The past and futures approaches for immunologic therapies in multiple sclerosis (MS) are discussed and why the past therapeutic approaches failed and what these failures could mean to the concepts of pathogenesis and trial design.
Review of Novel Immunotherapeutic Strategies for MS
TLDR
This chapter provides a compilation of novel immunotherapeutic strategies or new aspects of known immunotherAPEutic agents that have evolved in recent years and their immunopathogenetic rationale as well as the accompanying preclinical and clinical data to support their potential to endorse the currently available disease modifying drugs.
Developing therapeutics for the treatment of multiple sclerosis
TLDR
The future therapeutic options for MS will depend on improvements in understanding the precise factors involved in disease onset and progression and subsequently the development of oral therapeutics that translate sustained benefit from the preclinical context into clinical reality.
High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis
TLDR
The literature suggests that high-dose, high-frequency sc IFN beta-1a offers an effective option for treating patients with relapsing MS, with proven long-term safety and tolerability, and has a favourable benefit-to-risk ratio compared with other forms of IFNbeta.
Taenia crassiceps infection abrogates experimental autoimmune encephalomyelitis.
TLDR
The T. crassiceps-induced immune regulation decreased EAE severity by dampening T cell activation, proliferation and migration to the CNS, which was associated with both decreased MOG-specific splenocyte proliferation and IL-17 production and limited leukocyte infiltration into the spinal cord.
Actions of FTY720 (Fingolimod), a Sphingosine-1-Phosphate Receptor Modulator, on Delayed-Rectifier K+ Current and Intermediate-Conductance Ca2+-Activated K+ Channel in Jurkat T-Lymphocytes
TLDR
The perturbations by FTY720 on different types of K+ channels may contribute to the functional activities of immune cells, if similar findings appear in vivo.
...
1
2
3
...

References

SHOWING 1-10 OF 57 REFERENCES
The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors*
TLDR
The results suggest that FTY720, after phosphorylation, acts through sphingosine 1-phosphate signaling pathways to modulate chemotactic responses and lymphocyte trafficking.
Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis
TLDR
Radiological and clinical markers of disease activity were significantly decreased for at least 18 months after treatment, however, a third of patients developed antibodies against the thyrotropin receptor and carbimazole-responsive autoimmune hyperthyroidism.
Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis.
TLDR
Treatment with anti-VLA-4 Ab has multiple effects on the immune system and may be problematic in treating established autoimmune diseases such as MS, according to these results.
Mycophenolate mofetil treatment accelerates recovery from experimental allergic encephalomyelitis.
TLDR
This study shows MM was superior to CsA in the treatment of EAE and acted by reducing the inflammatory infiltrate, not by suppression of Ig response or by promotion of regulatory cells such as Th2 or Th3.
Amelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment
TLDR
The results suggested that the protective anti-inflammatory effect of treatment with FTY720 was, to a large extent, due to the inhibition of encephalitogenic T-cell responses and/or their migration into the central nervous system and may be a potential candidate for use in treating patients with MS.
Inhibition of experimental allergic encephalomyelitis in the Lewis rat by paclitaxel
TLDR
In vitro micellar PTX inhibited activation of encephalitogenic T cells by both specific antigen and mitogen, and may provide effective treatment with acceptable adverse effects with this agent in the treatment of inflammatory demyelinating disease.
Administration of Agonistic Anti-4-1BB Monoclonal Antibody Leads to the Amelioration of Experimental Autoimmune Encephalomyelitis1
TLDR
It is suggested that anti-4-1BB treatment during the induction phase inhibits autoreactive T cell immune responses rather than preventing T cell trafficking into the CNS, and 2A treatment also inhibits the relapse of EAE in a clinically relevant murine model of multiple sclerosis.
Effects of anti‐CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production
TLDR
A double-blind placebo-controlled trial of the chimeric monoclonal anti-CD4 antibody, cM-T412, demonstrated significant long-term reductions, lasting up to 12 months after the last treatment cycle in all CD4+ subsets studied, but with a relative preservation ofCD4+ memory cells as opposed to CD4– naive cells.
Suppression of Experimental Autoimmune Encephalomyelitis Using Peptide Mimics of CD281
TLDR
Two CD28 peptide mimics that selectively block B7:CD28/CTLA-4 costimulatory pathway interactions dramatically improved clinical signs of EAE, suppressing ongoing disease.
Prevention of Experimental Autoimmune Encephalomyelitis in Common Marmosets Using an Anti-IL-12p40 Monoclonal Antibody1
TLDR
It is demonstrated that in vivo neutralization of IL-12p40 using a novel Ab has beneficial effects in the myelin-induced EAE model in common marmosets and has a protective effect on the neurological dysfunction as well as on neuropathological changes normally observed in the brain and spinal cord of EAE-affected individuals.
...
1
2
3
4
5
...